Stellar Biotechnologies Announces Investor Relations Agreement

PORT HUENEME, CA--(Marketwire - Jan 18, 2012) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has retained TheBiotechPanel, Inc. (www.thebiotechpanel.com), a Florida-based company specializing in financial and investor relations and communications focused on Europe, to provide the Company with investor relations services.

The agreement between the Company and TheBiotechPanel (the "IR Agreement") is for an initial period of six months, renewable at the mutual agreement of both parties. TheBiotechPanel is a full and comprehensive provider of investor relations services, and will assist the Company in fostering productive, continuing dialogues with analysts, brokers, investors and other financial professionals.

TheBiotechPanel will receive a monthly retainer of US $8,000 during the term of the IR Agreement ($48,000 for first six months). The IR Agreement is subject to review and approval by the TSX Venture Exchange.

Darrell Brookstein, Stellar's Executive VP, Corporate Development & Finance, said, "We are very pleased to have Frank Rothmaier, the founder and editor of TheBiotechPanel.com and his experienced partner, Ray Campos, on board to help Stellar reach out to European investors as we move forward with our U.S. registration which will enable a new group of professional investors and analysts to review the merits of our securities. TheBiotechPanel will bring 'biopharma fluency' in German and Spanish, and enable us to reach tens of thousands of European retail investors with demonstrated interest in U.S. small-cap biotech companies."

Frank Rothmaier, founder and Managing Director of TheBiotechPanel, said, "I have been enthusiastically following the dynamic Stellar growth story for almost two years now, and have been identifying investors for their KLH, therapeutic vaccine and potential active immune platform story during that time. I'm excited to bring the Stellar team to present before our European investors. I believe institutional as well as retail investors will become quite interested in Stellar Biotechnologies as it develops to the next stage in 2012."

Stellar Biotechnologies, Inc. (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom of http://stellarbiotechnologies.com/investors/news_releases/.

TheBiotechPanel, Inc. is an investor and financial public relations firm specializing in small and micro-cap life sciences companies. TheBiotechPanel's goal is to build and maintain an informed investor audience, especially in Europe by increasing awareness about the company through TheBiotechPanel's established relationships with investment professionals, investment advisors, money managers, and market makers focused on the microcap market space for biotech, pharmaceutical and medical diagnostic and device companies.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.